Posts tagged oxyntomodulin analog
Transition Therapeutics reports TT401 trial results

Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported results of a Phase 2 clinical study of drug candidate, TT401, for the treatment of Type 2 diabetes.

TT401 is a once-weekly administered oxyntomodulin analog, with dual GLP-1 and glucagon agonist activity. TT401 development collaborator, Eli Lilly, performed the Phase 2 study, enrolling 420 Type 2 diabetes subjects into a 24-week study, consisting of a 12-week randomized blinded stage followed by a 12-week open-label stage.

Read More